Abstract

Traumatic brain injury (TBI) produces profound and lasting neuroinflammation that has both beneficial and detrimental effects. Recent evidence has implicated microRNAs (miRNAs) in the regulation of inflammation both in the periphery and the CNS. We examined the expression of inflammation associated miRNAs in the context of TBI using a mouse controlled cortical impact (CCI) model and found increased levels of miR-21, miR-223 and miR-155 in the hippocampus after CCI. The expression of miR-155 was elevated 9-fold after CCI, an increase confirmed by in situ hybridization (ISH). Interestingly, expression of miR-155 was largely found in neuronal nuclei as evidenced by co-localization with DAPI in MAP2 positive neurons. In miR-155 knock out (KO) mice expression of type I interferons IFNα and IFNβ, as well as IFN regulatory factor 1 and IFN-induced chemokine CXCL10 was decreased after TBI relative to wild type (WT) mice. Unexpectedly, miR-155 KO mice had increased levels of microglial marker Iba1 and increased neuronal degeneration as measured by fluoro-jade C (FJC) staining, suggesting a neuroprotective role for miR-155 in the context of TBI. This work demonstrates a role for miR-155 in regulation of the IFN response and neurodegeneration in the aftermath of TBI. While the presence of neuronal nuclear miRNAs has been described previously, their importance in disease states is relatively unknown. Here, we show evidence of dynamic regulation and pathological function of a nuclear miRNA in TBI.

Highlights

  • Traumatic brain injury (TBI) is a leading cause of death and disability worldwide

  • We have identified miR-155 as a TBI induced miRNA that promotes the type 1 IFN response

  • In the context of TBI, miR-155 is strongly expressed in neuronal nuclei, suggesting that it may regulate gene expression through non-canonical mechanisms

Read more

Summary

Introduction

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Inflammation in the brain of TBI patients has been found as long as 18 years following injury and likely contributes to long-term cognitive dysfunction (Johnson et al, 2013). Several clinical trials aimed at reducing overall inflammation using steroids, hypothermia, hypertonic saline and eicosanoids have failed to show therapeutic efficacy (Hinson et al, 2015). These failures highlight a need for a more nuanced understanding of inflammation and it’s regulation in the context of TBI

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call